Navigation Links
AACE Issues New Medical Guidelines for Proper and Ethical Use of Growth Hormone
Date:11/3/2009

JACKSONVILLE, Fla., Nov. 3 /PRNewswire-USNewswire/ -- Today the American Association of Clinical Endocrinologists (AACE) released new medical guidelines for the accurate diagnosis and effective ethical treatment of growth hormone deficiency in affected patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090324/DC88061LOGO-b)

Growth hormone replacement therapy has proven useful for children and adults with scientifically proven growth hormone deficiency. In recent years, however, growth hormone use for anti-aging and athletic enhancement has increased to the point that this use currently accounts for approximately 30 percent of growth hormone prescriptions in the United States (1). A number of professional athletes have now admitted or have been alleged to have used HGH to speed recovery from injury or to enhance performance. Anti-aging centers tout benefits of HGH to slow the aging process.

"Although there is not a wealth of medical data published concerning HGH as a recovery tool for injured athletes, it's certainly not an approved indication for use," Dr. David Cook, Interim Division Chief of Endocrinology at the Oregon Health & Science University, and co-author of the new medical guidelines said.

In addition to addressing the increasing misuse of growth hormone in anti-aging and sports, the AACE guidelines more importantly address the accurate diagnosis and effective therapy for growth hormone deficient patients, as well as new cut points or benchmarks for growth hormone testing.

"These guidelines are the result of recent advancements in our understanding of the benefits of growth hormone replacement for patients," Dr. Cook said.

Responsiveness to growth hormone therapy is often determined by many variables, such as age, sex, adiposity, and concurrent medications. However, even after accounting for these variables, there remain highly individual differences in the response to growth hormone.

"Controlled trials, using strict dosing regimes and measuring clinical end points, such as body composition and insulin sensitivity, have shown us that growth hormone dosing should be individualized, with close attention to avoiding side effects," Dr. Cook said.

The AACE guidelines also outline new cut points for stimulation testing of growth hormone deficiency. Stimulation testing measures normal secretion or low growth hormone secretion, making them an accurate barometer to gauge growth hormone deficiency.

"If the cut point is five and the highest response is four, then the patient is growth hormone deficient," Dr. Cook said. "Some tests also depend upon body mass index such as the Arginine + growth hormone releasing hormone stimulation test."

Despite a growing body of evidence on the benefits of growth hormone therapy, there is still considerable inconsistency in the United States in the clinical practice of growth hormone replacement for adults.

"There are multiple factors accounting for this," Dr. Cook said. "Such as the high cost of growth hormone therapy, the need for daily injections, the lack of awareness regarding its indications, diagnosis, long-term surveillance, and concerns about whether there are long-term risks involved."

Consequences of untreated growth hormone deficiency include cardiovascular complications, metabolic complications, osteopenia/osteoporosis, and diminished quality of life.

To view the AACE guidelines, please Click Here.

About AACE

AACE is a professional medical organization with more than 6,000 members in the United States and 92 other countries. Founded in 1991, AACE is dedicated to the optimal care of patients with endocrine problems. AACE initiatives inform the public about endocrine disorders. AACE also conducts continuing education programs for clinical endocrinologists, physicians whose advanced, specialized training enables them to be experts in the care of endocrine disease, such as diabetes, thyroid disorders, growth hormone deficiency, osteoporosis, cholesterol disorders, hypertension and obesity.

About the American College of Endocrinology (ACE)

The American College of Endocrinology (ACE) is the educational and scientific arm of the American Association of Clinical Endocrinologists (AACE). ACE is a scientific and charitable medical organization dedicated to promoting the art and science of clinical endocrinology for the improvement of patient care and public health. The American College of Endocrinology is the leader in advancing the care and prevention of endocrine and metabolic disorders by: providing professional education and reliable public health information; recognizing excellence in education, research and service; promoting clinical research; and defining the future of clinical endocrinology.

About Endocrine Practice

Endocrine Practice is the official scientific publication of the ACE and the AACE. It publishes the latest information in the treatment of diabetes, thyroid disease, obesity, growth hormone deficiency, sexual dysfunction, and osteoporosis, among others. The journal contains original articles, case reports, review articles, AACE Medical Guidelines for Clinical Practice, commentaries, editorials, and visual images. The total circulation of Endocrine Practice exceeds 5,300. Of these readers, 94 percent are physicians who treat endocrine-related disorders. Readership includes subscriptions in 84 countries, as well as many medical schools and research facilities.

(1) Lyle WG. Human growth hormone and anti-aging. Plast Reconstr Surg. 2002;110:1585-1589.

SOURCE American Association of Clinical Endocrinologists


'/>"/>
SOURCE American Association of Clinical Endocrinologists
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Impact of Counterfeits on Parallel Trade & Pharmaceutical Distribution: Issues, initiatives and insights for supply chain integrity
2. China National Medicines Corporation Issues Milestone Purchase Order for 12,000 STA Systems
3. FDA Issues Another Emergency Use Authorization for Commercial H1N1 Flu Test to Quest Diagnostics Focus Diagnostics
4. Unomedical Issues Worldwide Recall of Certain Manual Pulmonary Resuscitators
5. FDA Issues Complete Response Letter for Carisbamate
6. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
7. Society of Gynecologic Oncologists Issues White Paper on HPV Vaccines Impact on Cervical Cancer Prevention
8. Pennsylvania Agriculture Department Issues Quarantine for Allegheny County Horse Stable
9. FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents
10. Avon Protection Systems Issues Correction/Clarification on ST53 SCBA System
11. Pharmos Issues Business Update on Dextofisopam Trial and Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... -- Just 18 months after its February 2016 launch, market ... appointment of three new senior people to its rapidly ... and James Wright bring decades of ... Tammy Wynne joins as Director, Value ... has over ten years, experience in global market access ...
(Date:8/31/2017)... PM360,s annual Innovations Issue, published in ... innovations happening across the industry. Established six years ago, ... providing a comprehensive look at the newest and most ... innovative companies, startups, divisions, products, services, and strategies from ... "Everyone in this industry wants to do better—in all ...
(Date:8/25/2017)... -- Innovation Zed ( www.innovationzed.com ), an Irish medtech company, today announced that ... and Bassetlaw, England . The ... as part of a national NHS Test Bed programme exploring new models ... Innovation Zed ... InsulCheck Connect, a snap-on accessory for disposable insulin pen users, automatically collects ...
Breaking Medicine Technology:
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... with offices serving communities in northern Alabama and Georgia, is embarking on an ... prevention by utilizing modern early detection methods. , US Breast Cancer statistics ...
(Date:9/20/2017)... ... September 20, 2017 , ... Collins Concrete Coatings announced that ... rely on safety and cleanliness. This unique flooring system uses silver ion technology ... for centuries for its antimicrobial properties. Unlike antibiotics, which kill specific microorganisms, silver ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... company specializing in medical device compliance and commercialization, has just released a ... activities. , FDA is more adamant than ever about medical device, pharmaceutical, ...
(Date:9/20/2017)... Cleveland, Ohio (PRWEB) , ... September 20, 2017 ... ... commitment to customer service and innovation, the company recently unveiled a redesigned website. ... to further enrich the work of building owners, architects, contractors and other industry ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Honey Pot Company is ... goal is to ignite conversation via social media and word-of-mouth regarding vaginal health, ... declared September “Humans with Vaginas” month, releasing a video celebrating the power of ...
Breaking Medicine News(10 mins):